High incidence of hypertension in middle-aged French adults in the late 1990s

Journal of Human Hypertension

Volumn 22, Issue 3, 2008, Pages 211-213

  Meneton, P ^a   Heudes, D ^b   Bertrais, S ^c   Czernichow, S ^c   Galan, P ^c   Hercberg, S ^c   Menard J ^b  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c INSERM U557/INRA U1125/CNAM/Paris 13 SMBH/Centre Recherche Nutrition Humaine d'Ile de France ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTIOXIDANT; PLACEBO;

ADULT; AGE; ARTICLE; CARDIOVASCULAR RISK; CAUCASIAN; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CONTROL; FEMALE; FOLLOW UP; FRANCE; HIGH RISK POPULATION; HUMAN; HYPERTENSION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PREVALENCE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SEX DIFFERENCE; VOLUNTEER;

FEMALE; FRANCE; HUMANS; HYPERTENSION; INCIDENCE; MALE; MIDDLE AGED; PREVALENCE;

EID: 39449101460     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/sj.jhh.1002292     Document Type: Article

References (12)

1. Antikainen RL, Moltchanov VA, Chukwuma Sr C, Kuulasmaa KA, Marques-Vidal PM, Sans S et al. Trends in the prevalence, awareness, treatment and control fsof hypertension: The WHO MONICA Project. Eur J Cardiovasc Prev Rehabil 2006; 13: 13-29.
2. Radi S, Lang T, Lauwers-Cances V, Chatellier G, Fauvel JP, Larabi L et al. One-year hypertension incidence and its predictors in a working population: The IHPAF study. J Hum Hypertens 2004; 18 487-494.
3. Hercberg S, Preziosi P, Briancon S, Galan P, Triol I, Malvy D et al A primary prevention trial using nutritional doses of antioxidant vitamins and minerals in cardiovascular diseases and cancers in a general population: The SU.VI.MAX study - design, methods, and participant characteristics. SUpplementation bn VItamines et Mineraux AntioXydants. Control Clin Trials 1998; 19: 336-351.
4. Czernichow S, Bertrais S, Blacher J, Galan P, Briancon S, Favier A et al. Effect of supplementation with antioxidants upon long-term risk of hypertension in the SU.VI.MAX study: Association with plasma. antioxidant levels. J Hypertens 2005; 23: 2013-2018.
5. Lang T, de Gaudemaris R, Chatellier G, Hamici L, Diene E. Prevalence and therapeutic control of hypertension in 30 000 subjects in the workplace. Hypertension 2001; 38: 449-454.
6. Marques-Vidal P, Ruidavets JB, Amouyel P, Ducimetiere P, Areiler D, Montaye M et al. Change in cardiovascular risk factors in France, 1985-1997. Eur J Epidemiol 2004; 19: 25-32.
7. Rywik SL, Davis CE, Pajak A, Broda G, Folsom AR, Kawalec E et al. Poland and U.S. collaborative study on cardiovascular epidemiology hypertension in the community: Prevalence, awareness, treatment, and control of hypertension in the POL-MONICA Project and the U.S. Atherosclerosis Risk in Communities Study. Ann Epidemiol 1998; 8: 3-13.
8. Rywik SL, Williams OD, Pajak A, Broda G, Davis CE, Kawalec E et al Incidence and correlates of hypertension in the Atherosclerosis Risk in Communities (ARIC) study and the Monitoring Trends and Determinants of Cardiovascular Disease (POL-MONICA) project. J Hypertens 2000; 18: 999-1006.
9. Laurenzi M, Cirillo M, Panarelli W, Trevisan M, Stamler R, Dyer AR, et al.for The Gubbio Study Research Group. Baseline sodium-lithium counter-transport and 6-year incidence of hypertension. The Gubbio Population Study. Circulation 1997; 95: 581-587.
10. Laurenzi M, Trevisan M. Sodium-lithium counter-transport and blood pressure: The Gubbio Population Study. Hypertension 1989; 13 408-415.
11. Wolf-Maier K, Cooper RS, Banegas JR, Giampaoli S, Hense HW, Joffres M et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 2003; 289: 2363-2369.
12. Dannenberg AL, Garrison RJ, Kannel WB. Incidence of hypertension in the Framingham Study. Am J Public Health 1988; 78: 676-679.